305: Ignite Session 2B

Presentations:

• 2:00 PM – 2:05 PM Eastern Time

  Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
  

  Ignite Speaker: Christian Ammitzbøll, MD, PhD – Aarhus University Hospital
• 2:05 PM – 2:10 PM Eastern Time

  Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
  

  Ignite Speaker: Elisabeth Simader, MD – Department of Rheumatology , Medical University of Vienna
• 2:10 PM – 2:15 PM Eastern Time

  Development of Autoantibodies and Their Association with Flare-ups of Rheumatic Diseases in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population Following BNT162b2 mRNA COVID-19 Vaccination - Results of 1-year Prospective Follow-up Study
  

  Ignite Speaker: Tal Gazitt, MD – Carmel Hospital
• 2:15 PM – 2:20 PM Eastern Time

  Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases
  

  Ignite Speaker: Zachary Wallace, MD, MSc – Massachusetts General Hospital
• 2:20 PM – 2:25 PM Eastern Time

  COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
  

  Ignite Speaker: Mrinalini Dey, MRCP, MA, MBBCH – Queen Elizabeth Hospital, London & Institute of Life Course and Medical Sciences, University of Liverpool
• 2:25 PM – 2:30 PM Eastern Time

  Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Diseases
  

  Ignite Speaker: Silera Holguin Balbuena, MD – University of South Florida, Tampa
• 2:30 PM – 2:35 PM Eastern Time

  Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
  

  Ignite Speaker: Merav Heshin Bekenstein, MD – Tel Aviv Medical Center Israel
• 2:35 PM – 2:40 PM Eastern Time

  COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
  

  Ignite Speaker: Amit Saxena, MD – NYU School of Medicine
• 2:40 PM – 2:45 PM Eastern Time

  Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A
  

  Ignite Speaker: Francesco Ferro, MD – Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana